Georgia is currently home to 1996 active clinical trials, seeking participants for engagement in research studies. These trials take place at a variety of cities in the state, including Atlanta, Augusta, Decatur and Savannah. Whether you're a healthy volunteer interested in paid medical research or someone seeking trials related to a specific condition, the state offers a diverse array of opportunities in your vicinity.
2021 PMT iAge® Intervention Trial by Edifice Health
NCT04983017
Recruiting
This is a decentralized, double-blind, randomized, placebo-controlled study to assess the effectiveness of different dietary supplements in decreasing systemic chronic inflammation (SCI) and lowering inflammatory age (iAge®). iAge® is a metric for age-related chronic inflammation and immune function decline calculated from a standard blood draw utilizing immune phenotyping and artificial intelligence algorithms. SCI is a natural process that occurs within the body. It is believed to accelerate t... Read More
Gender:
All
Ages:
18 years and above
Trial Updated:
06/07/2022
Locations: Herman Clinical Research, LLC, Suwanee, Georgia
Conditions: Chronic Inflammation, Inflammaging
Register for Updates
A Pilot Study Investigating the Detection of Episodes of Severe Patient-Ventilator Asynchrony
NCT04550871
Recruiting
The goal of this study is to determine what percent of severe patient-ventilator asynchrony is detected in mechanically ventilated patients in the adult ICU and to determine delays in detecting those asynchronies by the staff that were correctly identified, and whether asynchrony status recorded during intermittent assessments by respiratory therapists is representative of periods in between such assessments.
Gender:
All
Ages:
18 years and above
Trial Updated:
05/25/2022
Locations: Northeast Georgia Medical Center, Gainesville, Georgia
Conditions: Respiratory Failure
Register for Updates
Optune Delivered Electric Field Therapy and Bevacizumab in Treating Patients With Recurrent or Progressive Grade 2 or 3 Meningioma
NCT02847559
Recruiting
The purpose of this research study is to determine the effects bevacizumab (the study drug) combined with Optune (the study device) tumor treatment field therapy has on meningiomas. Bevacizumab is considered investigational because the US Food and Drug Administration (FDA) has not approved its use for the treatment of meningiomas. The study drug is a medication that blocks the growth of new blood vessels. It is thought that the study drug may interfere with the growth of new blood vessels and th... Read More
Gender:
All
Ages:
18 years and above
Trial Updated:
05/25/2022
Locations: Piedmont Healthcare, Atlanta, Georgia
Conditions: Anaplastic (Malignant) Meningioma, Atypical Meningioma, Grade II Meningioma, Grade III Meningioma, Recurrent Meningioma, Supratentorial Meningioma
Register for Updates
Dipraglurant (ADX48621) for the Treatment of Patients With Parkinson's Disease Receiving Levodopa-based Therapy
NCT04857359
Recruiting
This study is designed to evaluate the safety and efficacy of dipraglurant in PD patients with dyskinesia (randomized 1:1 to receive active or placebo) for 12 weeks (1 week at 150 mg per day and 11 weeks at 300 mg per day). The primary efficacy assessment will be based on the Unified Dyskinesia Rating Scale (UDysRS). Patients who complete the 12-week blinded treatment period may have the option to roll into an open-label safety extension study for an additional 12-month treatment period.
Gender:
All
Ages:
Between 30 years and 85 years
Trial Updated:
05/18/2022
Locations: Emory University, Atlanta, Georgia
Conditions: Parkinson Disease, Dyskinesia, Drug-Induced, Dyskinesias
Register for Updates
Estetrol for the Treatment of Moderate to Severe Vasomotor Symptoms in Postmenopausal Women (E4Comfort Study I)
NCT04209543
Recruiting
This is a two-part study designed to evaluate the effect of Estetrol (E4) 15 or 20 mg, or placebo on the severity and frequency of vasomotor symptoms (VMS) (Efficacy Study Part) and the safety of E4 20 mg (Endometrial and General Safety Study Part)
Gender:
Female
Ages:
Between 40 years and 65 years
Trial Updated:
05/09/2022
Locations: Infinite Clinical Trials, Morrow, Georgia
Conditions: Vasomotor Symptoms, Menopausal Symptoms
Register for Updates
The Treatment in Pregnancy for Hepatitis C ("TiP-HepC") Registry
NCT05368974
Recruiting
Clinical interventions to reduce the risk of vertical transmission of hepatitis C virus (HCV) infection from mother to infant are highly limited. Direct-acting antiviral (DAA) medications have demonstrated excellent safety and efficacy in non-pregnant individuals, but there is a lack of data regarding the safety of these medications in pregnant women and the effectiveness of these medications in reducing mother-to-child transmission. Therefore, although HCV screening during pregnancy is now reco... Read More
Gender:
All
Ages:
All
Trial Updated:
05/06/2022
Locations: The Taskforce for Global Health, Atlanta, Georgia
Conditions: Hepatitis C
Register for Updates
Oscillation and Lung Expansion Therapy in Patients With COVID-19
NCT04582214
Recruiting
A Pilot Study of the Use of Oscillation and Lung Expansion (OLE) Therapy in Patients Hospitalized with COVID-19
Gender:
All
Ages:
18 years and above
Trial Updated:
05/04/2022
Locations: Emory University, Atlanta, Georgia
Conditions: COVID-19, Oscillation and Lung Expansion
Register for Updates
SYNCHRONISE: LVO Triage Timing and Outcome Study
NCT04608617
Recruiting
The objective of this study is to evaluate the impact of Viz LVO in hospital systems with non-interventional and interventional (spoke and hub) stroke centers on the timing and outcomes of patients with suspected acute ischemic stroke indicated for mechanical thrombectomy.
Gender:
All
Ages:
18 years and above
Trial Updated:
04/26/2022
Locations: Wellstar Neurosurgery, Atlanta, Georgia
Conditions: Stroke, Ischemic
Register for Updates
Open-label Safety Study of Dipraglurant (ADX48621) in Patients With Parkinson's Disease Receiving Levodopa-based Therapy
NCT05116813
Recruiting
This open-label study is designed to assess the long-term safety and tolerability of dipraglurant in PD patients for up to 52 weeks (at doses of 150-300 mg per day) for patients that have completed an Addex sponsored double-blind clinical trial of dipraglurant.
Gender:
All
Ages:
Between 30 years and 85 years
Trial Updated:
04/18/2022
Locations: Augusta University, Augusta, Georgia
Conditions: Parkinson Disease, Dyskinesia, Drug-Induced, Dyskinesias
Register for Updates
Prevent Maternal Mortality Using Mobile Technology
NCT05339867
Recruiting
Black women who reside in a rural area are at highest risk for maternal morbidity and mortality due to a combination of social and structural causes. The postpartum period is the most critical yet most neglected phase for preventing suboptimal or fatal maternal health outcomes. The goal of this project is to use a mobile app to provide personalized support and improve the lives of women during the early postpartum period. The information the study team gathers will help educate women and all who... Read More
Gender:
All
Ages:
Between 18 years and 45 years
Trial Updated:
04/15/2022
Locations: Morehouse School of Medicine, Atlanta, Georgia
Conditions: Post-Partum
Register for Updates
Study to Evaluate Effects of INL1 in Patients With Heart Failure and Reduced Ejection Fraction
NCT03875183
Recruiting
This is a multicenter, randomized, double-blind, placebo-controlled, dose-response trial in patients with chronic stable Heart Failure (HF) and reduced Left Ventricular Ejection Fraction (LVEF) to evaluate the efficacy and safety of three INL1 doses compared with placebo. Patients will be treated for approximately 12 weeks with one of three INL1 doses: 50 mg, 150 mg, 300 mg, or, placebo capsules, taken twice daily (BID).
Gender:
All
Ages:
Between 18 years and 75 years
Trial Updated:
03/28/2022
Locations: Grady Clinical Research Center, Atlanta, Georgia
Conditions: Heart Failure, Reduced Ejection Fraction
Register for Updates
Study of Safety and Efficacy of ANG-3070 in Chronic Kidney Disease
NCT04939116
Recruiting
The major objective is to demonstrate the safety and efficacy of ANG-3070 in patients with primary glomerular disease and persistent proteinuria.
Gender:
All
Ages:
18 years and above
Trial Updated:
03/22/2022
Locations: Davita Clinical Research, Columbus, Georgia
Conditions: Glomerular Disease, Proteinuria
Register for Updates